Korean Circ J.  2008 Apr;38(4):185-190. 10.4070/kcj.2008.38.4.185.

Are Statins Beneficial for Patients With Heart Failure?

• Pyun WB

• KMID: 2225814
• DOI: http://doi.org/10.4070/kcj.2008.38.4.185

Abstract

There is a tremendous amount of evidence about the beneficial roles of statins, as related to primary and secondary prevention, for patients with ischemic heart disease. Many cardiologists are prescribing these drugs to their patients regardless of the left ventricular systolic function, and especially for patients with old myocardial infarction. After the report on the post-hoc analysis of the Scandinavian Simvastatin Survival Study, there have been many reports about the roles of statins for the patients with heart failure from ischemic or non-ischemic etiologies. But most of these reports were non-randomized, observational, post-hoc subgroup analyses and small prospective short term studies, and the power of the evidence was too weak to set a guideline for statin therapy in patients with heart failure. The conclusions of the previous reports were that two large prospective randomized trials might shed light on choosing to administer statins. Last November, the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA) study was presented and many cardiologists believed that this study did not resolve the lack of evidence for the current practice of administering statins to heart failure patients with ischemic heart disease, but it proved the safety of administering 10 mg of rosuvastatin. So, we review the potential benefits of statins, beyond the cholesterol lowering effects in patients with heart failure, and we will reexamine the use of statins in patients with heart failure after the CORONA study.

Keyword

Statins; Heart failure

MeSH Terms

Cholesterol
Fluorobenzenes
Heart
Heart Failure
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Light
Myocardial Infarction
Myocardial Ischemia
Pyrimidines
Secondary Prevention
Simvastatin
Sulfonamides
Rosuvastatin Calcium
Cholesterol
Fluorobenzenes
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pyrimidines
Simvastatin
Sulfonamides

Reference

1. American Heart Association. Heart Disease and Stroke Statistics: 2005 update. 2005. Dallas: American Heart Association.

2. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community based population. JAMA. 2004. 292:344–350.

3. Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006. 47:332–337.

4. Torre-Amione G. The syndrome of heart failure: emerging concepts in the understanding of its pathogenesis and treatment. Curr Opin Cardiol. 1999. 14:193–195.

5. Raina A, Pickering T, Shimbo D. Statin use in heart failure: a cause for concern? Am Heart J. 2006. 152:39–49.

6. Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large scale outcome trial? J Am Coll Cardiol. 2002. 39:1567–1573.

7. Bohm M, Hjalmarson A, Kjekshus J, Laufs U, McMurray J, van Veldhuisen DJ. Heart failure and statins: why do we need a clinical trial? Z Kardiol. 2005. 94:223–230.

8. Kjekshus J, Dunselman P, Blideskog M, et al. A statin in the treatment of heart failure?: controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail. 2005. 7:1059–1069.

9. Cleland JG, Loh H, Windram J, Goode K, Clark AL. Threats, opportunities, and statins in the modern management of heart failure. Eur Heart J. 2006. 27:641–643.

10. Krum H, Latini R, Maggioni AP, et al. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol. 2007. 119:48–53.

11. Go AS, Lee WY, Yang J, Lo JC, Gurwitz JH. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA. 2006. 296:2105–2111.

12. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007. 357:2248–2261.

13. Khush KK, Waters DD. Effects of statin therapy on the development and progression of heart failure: mechanisms and clinical trials. J Card Fail. 2006. 12:664–674.

14. Uretsky BF, Thygesen K, Armstrong PW, et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation. 2000. 102:611–616.

15. Berton G, Cordiano R, Palmieri R, Pianca S, Pagliara V, Palatini P. C-reactive protein in acute myocardial infarction: association with heart failure. Am Heart J. 2003. 145:1094–1101.

16. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest. 2002. 110:285–288.

17. Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation. 2005. 111:2356–2363.

18. Rauchhaus M, Clark AL, Doehner W, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol. 2003. 42:1933–1940.

19. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003. 108:839–843.

20. Hasegawa H, Yamamoto R, Takano H, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol. 2003. 35:953–960.

21. Laufs U, Wassmann S, Schackmann S, Heeschen C, Bohm M, Nickenig G. Beneficial effects of statins in patients with non-ischemic heart failure. Z Kardiol. 2004. 93:103–108.

22. Tousoulis D, Antoniades C, Bosinakou E, et al. Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis. 2005. 178:359–363.

23. Tousoulis D, Antoniades C, Bosinakou E, et al. Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart. 2005. 91:27–31.

24. Qi XL, Stewart DJ, Gosselin H, et al. Improvement of endocardial and vascular endothelial function on myocardial performance by captopril treatment in postinfarct rat hearts. Circulation. 1999. 100:1338–1345.

25. Tousoulis D, Charakida M, Stefanadi E, Siasos G, Latsios G, Stefanadis C. Statins in heart failure: beyond the lipid lowering effect. Int J Cardiol. 2007. 115:144–150.

26. Keith M, Geranmayegan A, Sole MJ, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol. 1998. 31:1352–1356.

27. Kiowski W, Sutsch G, Hunziker P, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 1995. 346:732–736.

28. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005. 46:e1–e82.

29. Serebruany VL, Murugesan SR, Pothula A, et al. Increased soluble platelet/endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure: independence of disease etiology, and antecedent aspirin therapy. Eur J Heart Fail. 1999. 1:243–249.

30. Lipinski MJ, Abbate A, Fuster V, Vetrovec GW. Drug insight: statins for nonischemic heart failure: evidence and potential mechanisms. Nat Clin Pract Cardiovasc Med. 2007. 4:196–205.

31. Strehlow K, Wassmann S, Bohm M, Nickenig G. Angiotensin AT1 receptor over-expression in hypercholesterolaemia. Ann Med. 2000. 32:386–389.

32. Pliquett RU, Cornish KG, Peuler JD, Zucker IH. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation. 2003. 107:2493–2498.

33. Adabag AS, Nelson DB, Bloomfield HE. Effects of statin therapy on preventing atrial fibrillation in coronary disease and heart failure. Am Heart J. 2007. 154:1140–1145.

34. Hognestad A, Dickstein K, Myhre E, Snapinn S, Kjekshus J. Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. Am J Cardiol. 2004. 93:603–606.

35. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ 3rd, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation. 1998. 97:1708–1715.

36. Fuller SJ, Gillespie-Brown J, Sugden PH. Oncogenic src, raf, and ras stimulate a hypertrophic pattern of gene expression and increase cell size in neonatal rat ventricular myocytes. J Biol Chem. 1998. 273:18146–18152.

37. Nakagami H, Jensen KS, Liao K. A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med. 2003. 35:398–403.

38. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999. 13:2905–2927.

39. Martin JH, Krum H. Statins and clinical outcomes in heart failure. Clin Sci. 2007. 113:119–127.

40. Yamada T, Node K, Mine T, et al. Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study. Am Heart J. 2007. 153:1055.e1–1055.e8.

41. Cleland JG, Coletta AP, Nikitin NP, Clark AL. Clinical trials update from the American College of Cardiology: Darbepoetin alfa, ASTEROID, UNIVERSE, paediatric carvedilol, UNLOAD and ICELAND. Eur J Heart Fail. 2006. 8:326–329.

42. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997. 3:249–254.

43. Krum H, Bailey M, Meyer W, et al. Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: results of CIBIS II. Cardiology. 2007. 108:28–34.

44. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Ann Intern Med. 1998. 129:681–689.

45. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol. 2004. 93:1124–1129.

46. Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation. 2005. 112:357–363.

47. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? a meta-regression analysis. J Am Coll Cardiol. 2005. 46:1855–1862.

48. Krum H, Ashton E, Reid C, et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail. 2007. 13:1–7.

49. Yun KH, Park HY, Choi JH, et al. Comparison of efficacy of safety after administration high potency statin to high risk patients: rosuvastatin 10 mg versus atorvastatin 20 mg. Korean Circ J. 2007. 37:154–160.